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assurance, to limit the required resources, and to reduce the 
effect of differences in patient positioning between the planning 
CT and treatment. The patient is treated both prone and supine 
under a 1 cm clear plastic sheet positioned 20 cm from their 
surface used to increase skin dose. The first patient treated using 
this technique at the TBCC was a 16-year-old male with sickle-
cell anemia. As gonadal shielding was desirable for this patient, 
our extended SSD lateral field technique was not an option. Our 
optimized VMAT technique allowed us to provide a reasonable 
amount of gonadal shielding using MLCs. 
Results:  Dose to the gonads was further reduced using a physical 
shield made of coated lead positioned above the gonads using an 
in-house designed device. The combined effect of these two 
types of shielding allowed us to reduce dose to testis from the 
prescription of 300 cGy to approximately 100 cGy, without over-
modulating the treatment fields or compromising dose 
uniformity to the rest of the body. 
Conclusions: In conclusion, a new TBI technique has been 
developed using VMAT delivery that is optimized to patient 
anatomy. In addition to a safe and more comfortable patient 
environment, this technique allows for shielding of organs at risk, 
if desired by the physician, as was the case for a recent patient 
at the TBCC – a pediatric sickle-cell anemia patient requiring 
scrotal shielding.
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Purpose:  Tumour metabolism is a promising area of cancer 
research which is investigated to develop strategies for PrCa 
prevention and sensitization to cytotoxic therapy. AMP-kinase 
(AMPK) is a master regulator of cellular metabolism and a well-
studied target for metabolism modulating therapeutics. It 
inhibits energy expenditure through anabolic events and 
stimulates substrate uptake and catabolic activities to increase 
energy availability. We showed that AMPK also senses genotoxic 
stress. It is activated downstream of Ataxia Telangiectasia 
Mutated (AMT) and leads to, i) induction of p53 and cyclin-
dependent kinase inhibitors p21cip1/p27kip1 and inhibition of 
cell cycle and proliferation and ii) blockade of protein 
biosynthesis and survival through inhibition of the AKT—mTOR 
pathway. 
We found the anti-diabetic biguanide metformin (MET) and the 
metabolite of aspirin Salicylate (SAL) activate AMPK through 
separate mechanisms and suppress de novo lipogenesis, which is 
required for cellular growth and cell division . Combined 
treatment with SAL + MET enhanced AMPK activity, suppressed 
lipogenesis and inhibited PrCa proliferation and clonogenic 
survival significantly more than each agent alone. Interestingly, 
retrospective studies link MET and aspirin with improved 
responses to RT. 
Methods and Materials:  Androgen sensitive (22RV1) and 
insensitive (PC3) PrCa cells were treated with SAL, MET and SAL+ 
MET without or with increasing doses of radiotherapy (RT) (0-8 
Gy) and were subjected to proliferation, clonogenic survival and 
immunoblotting (IB) experiments. Also, cells were grafted into 
flanks of immunosuppressed nude mice, treated with SAL, MET 
and SAL+MET without and with RT (10 Gy) and left to grow for 
eight weeks to investigate effects of treatment on tumour 
growth kinetics and biomarkers of response. 
Results:  SAL and MET caused a significant inhibition of 
proliferation and clonogenic survival in both cell lines, activated 
AMPK and inhibited the mTOR pathway. Combined treatment 
(SAL+ MET) produced synergistic activation of AMPK, inhibition 
of mTOR and PrCa clonogenic survival. SAL alone sensitized PrCa 
cells to RT and increase activation of the ATM-AMPK pathway. 
Importantly, the combined SAL+MET treatment enhanced 
significantly the sensitivity of PrCa cells to RT compared to each 
agent alone. Ongoing experiments evaluate the effects of 
combined SAL+ MET treatment on tumour growth kinetics.  
Conclusions:  Early results on the investigation of combined SAL+ 
MET treatment indicate that this may be a promising therapy 
against PrCa tumour growth and radio-resistance. The two agents 
are extensively-used, well-tolerated and economical 
therapeutics and there are no reports associating them with 
increase RT toxicity. If positive, our studies will generate the 
first basis for future rapid clinical investigation of combined SAL+ 
MET with RT in PrCa. 
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Purpose: Use of SBRT to treat metastatic tumours is increasing, 
despite no randomized evidence. This project reviews the 
outcomes of treating extracranial NSCLC metastases with SBRT 
from a single institution. 
Methods and Materials: One hundred and eight patients with 
metastatic NSCLC were treated between 2009 and 2015. 
Indications for treatment were: 1) oligometastases, where the 
goal was to irradiate all tumour sites; 2) oligoprogression, where 
the goal was to irradiate only tumours which were progressing 
while all other tumours were stable on observation or systemic 
therapy; and 3) for dominant tumours, where the goal was to 
optimize local control, even if other tumours were progressing. 
Outcomes of interest were local control (LC), overall survival 
(OS), progression-free survival (PFS), and time to change 
systemic therapy (TTCST). 
Results: Median age was 69.0 years. Median follow up time was 
11.3 months. Sixty-six patients were treated for oligometastases, 
20 for oligoprogression, and 22 for dominant tumour/local 
control. Thirteen patients had targeted oral therapy, and 51 had 
chemotherapy prior to SBRT. Eleven were on systemic therapy 
(four targeted oral therapy and seven chemotherapy) at time of 
SBRT. A total of 165 lesions were treated (44 lung, 60 spine, 27 
non-spine bone, 15 liver, 15 adrenal, four other sites). Median 
SBRT dose/fractions was 35 Gy/4 fractions. Median BED10 was 
59.5 Gy, although 61 lesions (37%) were treated with BED10 of ≥ 
100 Gy. LC at one year and two years was 80.2% and 64.4%, 
respectively. Univariate analyses revealed BED10 ≥ 100 Gy (p = 
0.0142), tumour size ≤ 4 cm (p = 0.0012), and lung tumour (p = 
0.0421) to predict for higher LC. Two year LC was 90.3% versus 
52.1% for tumours treated with BED10 ≥ 100 Gy versus < 100 Gy. 
Median OS was 27.3 months. Indication for treatment 
independently predicted for OS (p = 0.0045) with 
oligometastases patients living the longest, followed by 
oligoprogression, and then dominant tumour/local control 
(median OS of 39.3 months, 21.1 months, and 11.8 months, 
respectively). Median PFS was 4.4 months, with indication for 
treatment (p = 0.0013) being independently predictive (median 
PFS of 7.6 months, 3.2 months, and 2.3 months for 
oligometastases, oligoprogression, and dominant tumour/local 
control, respectively). Median TTCST was not reached for the 
whole cohort. The probability of starting or changing systemic 
therapy was 23.5% at one year. Indication for treatment was 
predictive (p = 0.0022), with the probability of changing systemic 
therapy strategy at one year being 11%, 43.9%, and 45.5% for 
patients treated for oligometastases, oligoprogression, and 
dominant tumour/local control, respectively. Seventeen 
patients (16%) received further SBRT at time of progression. 
Conclusions: In patients with NSCLC extracranial metastases 
treated with SBRT, those with oligometastases have the longest 
OS, PFS, and TTCST compared to those treated for 
